• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    President & CEO Palasis Maria sold $13,944 worth of shares (1,565 units at $8.91), decreasing direct ownership by 0.14% to 1,098,435 units (SEC Form 4)

    7/14/25 9:27:40 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care
    Get the next $LYRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Palasis Maria

    (Last) (First) (Middle)
    C/O LYRA THERAPEUTICS, INC.
    480 ARSENAL WAY

    (Street)
    WATERTOWN MA 02472

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Lyra Therapeutics, Inc. [ LYRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    07/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/10/2025 S(1) 1,565 D $8.91 1,098,435 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
    /s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis 07/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LYRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LYRA

    DatePrice TargetRatingAnalyst
    5/7/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    5/7/2024$10.00 → $0.50Buy → Hold
    Jefferies
    5/7/2024Buy → Underperform
    BofA Securities
    5/6/2024Outperform → Mkt Perform
    William Blair
    10/6/2023$15.00Buy
    BTIG Research
    8/31/2023$12.00Buy
    H.C. Wainwright
    5/24/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $LYRA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.

    SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/25/25 4:24:13 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.

    SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/18/25 4:14:27 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.

    SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/13/25 5:05:54 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lyra Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

    5/7/24 6:26:06 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously

    5/7/24 6:25:25 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics downgraded by BofA Securities

    BofA Securities downgraded Lyra Therapeutics from Buy to Underperform

    5/7/24 6:25:00 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

    Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

    12/3/24 8:00:00 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no product-related serious adverse events and general consistency with the primary treatment phase  WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate up

    11/12/24 4:01:58 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

    -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN

    10/15/24 7:00:00 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $LYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Waksal Harlan bought $74,095 worth of shares (25,000 units at $2.96), increasing direct ownership by 11% to 261,966 units (SEC Form 4)

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    11/13/23 5:29:27 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Large owner Perceptive Advisors Llc sold $182,515 worth of shares (45,875 units at $3.98) (SEC Form 4)

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    11/13/25 5:07:48 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Large owner Perceptive Advisors Llc sold $344,219 worth of shares (70,390 units at $4.89) (SEC Form 4)

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    11/10/25 5:08:46 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by President & CEO Palasis Maria

    4/A - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    10/8/25 4:30:03 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

    SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/14/24 7:48:39 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

    SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/14/24 5:49:14 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Leadership Updates

    Live Leadership Updates

    View All

    Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

    Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

    12/3/24 8:00:00 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care